Kyowa Hakko Kirin Suspends Recruitment For ARQ197 Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin announced it has suspended recruitment of new patients for the Phase III trials of ARQ197 (tivantinib) for interstitial lung disease involving Japan, Korea, and Taiwan due to recommendations from the safety monitoring committee.